Dry Eye Syndrome (DES) Therapeutics Market Report

Dry Eye Syndrome (DES) Therapeutics Market Report, By Product Type (Cyclosporine, Oral Corticosteroid, Artificial Tears, Omega Supplements and Punctal Plugs), Disease Type (Evaporative Dry Eye Syndrome and Aqueous Dry Eye Syndrome) and Geography - Global Market Share, Trend Analysis & Forecast , 2019 - 2028

Report Code : hc1880 | Publish Date : Jan, 2019 | Industry : Healthcare | Geography : Global


Dry eye disease is characterized by instability of the tear film that can be due to insufficient amount of tear production or due to poor quality of tear film, which results in increased evaporation of the tears. Dry eye therefore can mainly be divided into two groups, namely, aqueous production deficient dry eye disease and evaporative dry eye disease. Furthermore, the clinical manifestations of dry eye disease can be highly variable; hence the diagnosis is often based on a combination of symptoms, signs, and clinical tests, given that any one of these alone would miss a significant number of patients. Similarly, the treatment must often be tailored to each patient by targeting the specific mechanisms involved in his or her disease. Additionally, in 2017, based on the America Journal of Ophthalmology, more than 16 million U.S. adults were diagnosed with dry eye disease. Whereas, twice as many women had been diagnosed than men. Moreover, the rising presence of dry eye disease in developed economies and increasing prevalence are adding fuel to DES therapeutics market in future.

Dry Eye Syndrome Therapeutics Market Outlook

Growing number of eye care centers, technological advancements in DES therapeutics, High prevalence and rise in incidence rates of dry eye disease are some the major factors driving the growth of the DES therapeutics market. On the other hand, factors such as alternative therapies and high cost of specialty dry eye products are hampering the growth of the market.

Dry Eye Syndrome Therapeutics Segmental Overview

The DES therapeutics market is segmented by product type, disease type and geography.


Dry Eye Syndrome Therapeutics market by Product Type 

The products discussed in this report are cyclosporine, oral corticosteroid, artificial tears, omega supplements, punctal plugs and others. Furthermore, punctual plugs segment is classified into removable and dissolvable. Likewise, others segment include lid wipes, eye mask and specialized eye wares. Among various product types, the cyclosporine dominated the DES therapeutics market in 2018 and is also projected to lead the market by 2025. There are few alternatives which are as effective as cyclosporine which is helping the drug to hold strong dominance in the market. 

Dry Eye Syndrome Therapeutics market by Disease Type

The various disease types of the DES therapeutics market are covered in the report such as evaporative dry eye syndrome and aqueous dry eye syndrome. The aqueous dry eye syndrome segment dominated the market in 2018. This syndrome is caused by the tear gland damage, increase in the age and when the lacrimal gland fails to produce enough tears to coat the surface of the eye. Whereas, the market for evaporative dry eye syndrome is also projected to increase rapidly. 

Dry Eye Syndrome Therapeutics market by Geography 

The DES therapeutics market report is studied across the key countries of North America, Europe, Asia Pacific and Rest of the World. The market for DES therapeutics is dominated by North America in 2018. The region occupied largest market in dry eye disease market, owing to large patient pool, increasing per capita health care expenditure and increasing investment of key players in the market in this region. Furthermore, Europe is the second major market for DES therapeutics. The market of Europe was dominated by Germany. The strong performance of eye care markets such as standard and allergy eye care are recorded in Germany, due to the growing number of consumers being affected by dry eye, rising prevalence of allergies among the German population and growing population.

Dry Eye Syndrome Therapeutics Market Key Players

The key players profiled in the global DES therapeutics market are Allergan Plc, AFT pharmaceuticals, Akorn, Inc, Bausch Health Companies Inc, Rohto Pharmaceutical Co., Ltd., Similasan Corporation, I-Med Pharma Inc, Johnson and Johnson Vision care, Inc. (Johnson & Johnson), Medicom Healthcare, Alcon Laboratories, Inc. (Novartis AG), OASIS Medical, Otsuka Pharmaceutical Co., Ltd. (Otsuka Holdings), Reckitt Benckiser Group PLC, Santen Pharmaceutical Co Ltd, Scope Ophthalmics Ltd, Sentiss Pharma Private limited, Shire Plc, Thea Pharmaceuticals Limited, Bayer AG, Sun Pharmaceutical Industries Limited, among others. New product launches, research and development and mergers & acquisitions are the key strategies adopted by market players to ensure their growth in the market. 

Dry Eye Syndrome Therapeutics Market Developments

June 2018: Bausch Health Company launched Soothe Xtra Protection (XP) Preservative free lubricant eye drops, expanding its portfolio of eye health products to meet the growing demand of dry eye symptom relief without the use of preservatives

July 2018: Allergan plc, announced the launch of a new over-the-counter (OTC) artificial tear formulation, REFRESH REPAIR lubricant eye drops. The first and only artificial tear in the U.S. formulated with carboxymethylcellulose (CMC), hyaluronic acid, and osmoprotectants, REFRESH REPAIR is the latest addition to the REFRESH portfolio

September 2018: AFT Pharmaceuticals Ltd (AFT) commercializes NovaTears across Australia. AFT announced that NovaTears, its new preservative-free eye lubricant and tear film stabilizer for the treatment of evaporative dry eye (EDE), has been listed on the Australian pharmaceutical benefits scheme (PBS)

August 2017: Johnson & Johnson Vision announced a definitive agreement to acquire TearScience, a privately held medical device manufacturer dedicated to evaluating meibomian gland health and treating meibomian gland dysfunction (MGD)

The DES therapeutics market is segmented by product type, disease type and geography. The products discussed in this report are cyclosporine, oral corticosteroid, artificial tears, omega supplements, punctal plugs and others. Furthermore, punctual plugs segment is classified into removable and dissolvable. Likewise, others segment include lid wipes, eye mask and specialized eye wares. Among various product types, the cyclosporine dominated the DES therapeutics market in 2018 and is also projected to lead the market by 2025. There are few alternatives which are as effective as cyclosporine which is helping the drug to hold strong dominance in the market.

By disease types, the DES therapeutics market is segmented into evaporative dry eye syndrome and aqueous dry eye syndrome. The aqueous dry eye syndrome segment dominated the market in 2018. This syndrome is caused by the tear gland damage, increase in the age and when the lacrimal gland fails to produce enough tears to coat the surface of the eye. Whereas, the market for evaporative dry eye syndrome is also projected to increase rapidly.

Geographically, the DES therapeutics market is studied across the key countries of North America, Europe, Asia Pacific and Rest of the World. The market for DES therapeutics is dominated by North America in 2018. The region occupied largest market in dry eye disease market, owing to large patient pool, increasing per capita health care expenditure and increasing investment of key players in the market in this region. Furthermore, Europe is the second major market for DES therapeutics. The market of Europe was dominated by Germany. The strong performance of eye care markets such as standard and allergy eye care are recorded in Germany, due to the growing number of consumers being affected by dry eye, rising prevalence of allergies among the German population and growing population.

Why to buy this report:

  • The report offers changing market dynamics in the DES therapeutics market, presenting historical, current and projected market size in terms of value (USD Million)
  • The research study provides an in-depth analysis of the industry value chain focusing on the peer and parent markets of DES therapeutics, such as artificial tears market, aqueous dry eye syndrome market,
  • It presents a comprehensive assessment of geographical regions exhibiting promising growth, potential and niche segments, and a neutral perspective on the DES therapeutics market performance
  • The report also offers strategic recommendations in key business segments based on the market estimations and competitive landscape, mapping the key common trends of DES therapeutics market